Green light for Alligator Bioscience and Aptevo Therapeutics
Swedish Alligator Bioscience has developed the bispecific antibody ALG.
APV-527 together with American biotech Aptevo Therapeutics. Recently, US authorities have given the project a green light to proceed into the clinical phase.
The companies will now initiate a phase I trial with the candidate in solid tumours.
BioStock reached out to Alligator’s CEO Søren Bregenholt for.